Literature DB >> 16847523

[Ethical issues about seroprevalence studies on viral hepatitis].

Rosangela Gaze1, Diana Maul de Carvalho, Clara Fumiko Tachibana Yoshida, Luiz Fernando Rangel Tura.   

Abstract

BACKGROUND: Epidemiological studies on viral hepatitis (VH) using new technologies raise ethical issues especially concerning community-based studies on seroprevalence (CSS), sentinel surveillance-based studies (SBS) the use of blood-bank registers (BBR) and serum stocks (SS).
METHODS: Positive (PA) and negative (NA) aspects of these different designs are discussed, pointing to alternatives, according to Resolution CNS n masculine 196/96.
RESULTS: Priority for research is justified by VH magnitude, severity, and vulnerability, and need for development of diagnosis/therapy protocols and prevention/control strategies. With respect to CSS, PA was identified as: subject autonomy; adequate samples and as NA: costs override benefits, and availability of information from other sources. In relation to SBS, PA are: VH monitoring has lower operational costs than CSS; absence of additional injuries to subject; while NA is: relative restriction of representativeness. For BBR, PA is: the low cost of monitoring of HBV/HCV in blood donors and with no additional risk. PA has limited representativeness. SS studies present as PA: benefits higher than risks/costs; possibility of identification of new morbidity and offering of adequate diagnosis and treatment. NA is: biological material and research data can be used for other researches.
CONCLUSION: The choice of study designs must take into account arguments for ethical investigation and consensus on the use of new technology.

Entities:  

Mesh:

Year:  2006        PMID: 16847523     DOI: 10.1590/s0104-42302006000300017

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  1 in total

Review 1.  Ethical issues in public health surveillance: a systematic qualitative review.

Authors:  Corinna Klingler; Diego Steven Silva; Christopher Schuermann; Andreas Alois Reis; Abha Saxena; Daniel Strech
Journal:  BMC Public Health       Date:  2017-04-04       Impact factor: 3.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.